Review of neuromuscular blocking agents

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Header Abstract Content Author and article information References Comments

Record: found
Abstract: found
Poster: found

Is Open Access

Review of neuromuscular blocking agents

Published

poster

Author(s): Maneesh Singh ¹ ^,

Publication date (Electronic preprint): 14 September 2024

Journal: ScienceOpen Posters

Publisher: ScienceOpen

Bookmark

Abstract

Content

Author and article information

Journal

Title: ScienceOpen Posters

Publisher: ScienceOpen

Publication date (Electronic preprint): 14 September 2024

Affiliations

[1 ] Kansas City university;

Author notes

[* ]Email: meshusingh@ 123456kansascity.edu .

Author information

Maneesh Singh https://orcid.org/0000-0003-4859-2546

Article

DOI: 10.14293/P2199-8442.1.SOP-.PIWBDA.v1

SO-VID: 6ef70e6f-3339-49c4-bac1-2097467fd059

License:

This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

History

Date received : 14 September 2024

References

Andersson M. L., Møller A. M., Wildgaard K.. Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review. Anaesthesia. Vol. 74(4):518–528. 2019. Wiley. [Cross Ref]
Thilen S.R., Ng I.C., Cain K.C., Treggiari M.M., Bhananker S.M.. Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine. British Journal of Anaesthesia. Vol. 121(2):367–377. 2018. Elsevier BV. [Cross Ref]
Evaluation of Residual Neuromuscular Block Using Train-of-Four and Double Burst Stimulation at the Index Finger: Retraction Notice. Anesthesia & Analgesia. Vol. 128(1)2019. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]
Gijsenbergh Francois, Ramael Steven, Houwing Natalie, van Iersel Thijs. First Human Exposure of Org 25969, a Novel Agent to Reverse the Action of Rocuronium Bromide. Anesthesiology. Vol. 103(4):695–703. 2005. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]
Pühringer Friedrich K., Rex Christopher, Sielenkämper Andreas W., Claudius Casper, Larsen Per Bo, Prins Martine E., Eikermann Matthias, Khuenl-Brady Karin S.. Reversal of Profound, High-dose Rocuronium-induced Neuromuscular Blockade by Sugammadex at Two Different Time Points: An International, Multicenter, Randomized, Dose-finding, Safety Assessor-blinded, Phase II Trial. Anesthesiology. Vol. 109(2):188–197. 2008. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]
Fink Heidrun, Schaller. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evidence. 2013. Informa UK Limited. [Cross Ref]
Staals L.M., Snoeck M.M.J., Driessen J.J., van Hamersvelt H.W., Flockton E.A., van den Heuvel M.W., Hunter J.M.. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study †. British Journal of Anaesthesia. Vol. 104(1):31–39. 2010. Elsevier BV. [Cross Ref]

Comments

Comment on this article

[1] Andersson M. L., Møller A. M., Wildgaard K.. Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review. Anaesthesia. Vol. 74(4):518–528. 2019. Wiley. [Cross Ref]

[2] Thilen S.R., Ng I.C., Cain K.C., Treggiari M.M., Bhananker S.M.. Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine. British Journal of Anaesthesia. Vol. 121(2):367–377. 2018. Elsevier BV. [Cross Ref]

[3] Evaluation of Residual Neuromuscular Block Using Train-of-Four and Double Burst Stimulation at the Index Finger: Retraction Notice. Anesthesia & Analgesia. Vol. 128(1)2019. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]

[4] Gijsenbergh Francois, Ramael Steven, Houwing Natalie, van Iersel Thijs. First Human Exposure of Org 25969, a Novel Agent to Reverse the Action of Rocuronium Bromide. Anesthesiology. Vol. 103(4):695–703. 2005. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]

[5] Pühringer Friedrich K., Rex Christopher, Sielenkämper Andreas W., Claudius Casper, Larsen Per Bo, Prins Martine E., Eikermann Matthias, Khuenl-Brady Karin S.. Reversal of Profound, High-dose Rocuronium-induced Neuromuscular Blockade by Sugammadex at Two Different Time Points: An International, Multicenter, Randomized, Dose-finding, Safety Assessor-blinded, Phase II Trial. Anesthesiology. Vol. 109(2):188–197. 2008. Ovid Technologies (Wolters Kluwer Health). [Cross Ref]

[6] Fink Heidrun, Schaller. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evidence. 2013. Informa UK Limited. [Cross Ref]

[7] Staals L.M., Snoeck M.M.J., Driessen J.J., van Hamersvelt H.W., Flockton E.A., van den Heuvel M.W., Hunter J.M.. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study †. British Journal of Anaesthesia. Vol. 104(1):31–39. 2010. Elsevier BV. [Cross Ref]